Active Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 純度> 97%
- 下載 英文說明書 中文說明書
- 規格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1080 ¥ 2700 ¥ 5400 ¥ 16200 ¥ 40500
- Figure. Gene Sequencing (Extract)
- Figure. SDS-PAGE
- Figure. Western Blot
- 通過ISO 9001、ISO 13485質量體系認證
Figure. The binding activity of VEGFR2 with VEGFC.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) also known as kinase insert domain receptor is a VEGF receptor. There are three main subtypes of VEGFR, numbered 1, 2 and 3. All members of the VEGF family stimulate cellular responses by binding to VEGF receptors on the cell surface, causing them to dimerize and become activated through transphosphorylation. VEGFR2 appears to mediate almost all of the known cellular responses to VEGF. Besides, Vascular Endothelial Growth Factor C (VEGFC) has been identified as an interactor of VEGFR2, thus a binding ELISA assay was conducted to detect the interaction of recombinant human VEGFR2 and recombinant human VEGFC. Briefly, VEGFR2 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to VEGFC-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-VEGFR2 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of VEGFR2 and VEGFC was shown in Figure 1, and this effect was in a dose dependent manner.
Figure. Cell proliferation of ECV-304 cells inhibit by VEGFR2.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) also known as kinase insert domain receptor acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. VEGFR2 functions as the primary mediator of vascular endothelial growth factor activation in endothelial cells. Regulation of VEGFR-2 expression appears critical in mitogenesis, differentiation, and angiogenesis. To test the effect on inhibit the VEGF-dependent proliferation of endothelium cells, ECV-304 cells were seeded into triplicate wells of 96-well plates at a density of 5,000 cells/well and allowed to attach, replaced with serum-free overnight, then the medium was replaced with 2% serum standard DMEM?including 1μg/mL Vascular Endothelial Growth Factor C (VEGFC) and various concentrations of recombinant human VEGFR2. After incubated for 96h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10μL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37℃. Proliferation of ECV-304 cells after incubation with VEGFR2 for 96h observed by inverted microscope was shown in Figure 2. Cell viability was assessed by CCK-8 (Cell Counting Kit-8 ) assay after incubation with recombinant VEGFR2 for 96h. The result was shown in Figure 2. It was obvious that VEGFR2 significantly inhibit cell viability of ECV-304.
(A) ECV-304 cells cultured in DMEM, stimulated with 10ng/mL VEGFR2 for 96h;
(B) Unstimulated ECV-304 cells cultured in DMEM for 96h.
Figure. VEGFR2 inhibit VEGF-dependent proliferation of ECV-304 cells.
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
|編號||適用物種：Homo sapiens (Human，人)||應用(僅供研究使用，不用于臨床診斷！)|
|EPB367Hu61||血管內皮生長因子受體2(VEGFR2)真核蛋白||Positive Control; Immunogen; SDS-PAGE; WB.|
|RPB367Hu01||血管內皮生長因子受體2(VEGFR2)重組蛋白||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAB367Hu01||血管內皮生長因子受體2(VEGFR2)多克隆抗體||WB; IHC; ICC; IP.|
|LAB367Hu81||血管內皮生長因子受體2(VEGFR2)多克隆抗體(異硫氰酸熒光素標記)||WB; IHC; ICC; IF.|
|LAB367Hu71||血管內皮生長因子受體2(VEGFR2)多克隆抗體(生物素標記)||WB; IHC; ICC.|
|MAB367Hu22||血管內皮生長因子受體2(VEGFR2)單克隆抗體||WB; IHC; ICC; IP.|
|MAB367Hu21||血管內皮生長因子受體2(VEGFR2)單克隆抗體||WB; IHC; ICC; IP.|
|HEB367Hu||血管內皮生長因子受體2(VEGFR2)檢測試劑盒(酶聯免疫吸附試驗法,高敏型)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|SEB367Hu||血管內皮生長因子受體2(VEGFR2)檢測試劑盒(酶聯免疫吸附試驗法)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|APMIS||Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway [PubMed: 23398358]|
|Acta Biomater||Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470]|
|Acta Biomaterialia||Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470]|
|Regenerative Biomaterials||The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic [10.1093/rb/rbx028]|
|International Journal of Immunopathology and Pharmacology||VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these?… [Pubmed:29985074]|
|JOURNAL OF DERMATOLOGICAL TREATMENT||Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris [Pubmed: 32043381]|
|Journal of Genetic Engineering and Biotechnology||Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells |